MAVER-1Homo sapiens (Human)Cancer cell line
Also known as: MAntle cell VERona-1, MAVER, Maver1, MAVER1, Maver-1
🤖 AI SummaryBased on 6 publications
Quick Overview
MAVER-1 is a mantle cell lymphoma cell line used in research for B-cell malignancies.
Detailed Summary
MAVER-1 is a mantle cell lymphoma (MCL) cell line derived from a human patient. It is widely used in research to study the molecular mechanisms of B-cell malignancies, particularly in the context of therapeutic resistance and targeted therapies. MAVER-1 has been utilized in studies investigating the efficacy of BCL-2 inhibitors like venetoclax and the role of the NF-κB pathway in MCL progression. The cell line exhibits specific genetic and phenotypic characteristics, including the t(11;14) translocation, which is a hallmark of MCL. Research involving MAVER-1 has contributed to understanding the complex interplay between the tumor microenvironment and drug resistance mechanisms, particularly in relation to Bcl-xL and Bcl-2 pathways. MAVER-1 is also used to evaluate the effectiveness of novel therapeutic strategies targeting the BCR signaling pathway and the PI3K/AKT/mTOR axis.
Research Applications
Study of B-cell malignanciesInvestigation of therapeutic resistance mechanismsEvaluation of BCL-2 inhibitors (e.g., venetoclax)Analysis of NF-κB pathway involvement in MCL progressionAssessment of BCR signaling pathway targetingResearch on PI3K/AKT/mTOR axis modulation
Key Characteristics
Expresses BCL-2 and is sensitive to BCL-2 inhibitorsCarries the t(11;14) translocationUsed in studies of drug resistance and microenvironment interactionsRelevant for understanding Bcl-xL and Bcl-2 pathway dynamics
Generated on 6/17/2025
Basic Information
| Database ID | CVCL_1831 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Peripheral blood[UBERON:UBERON_0000178] |
Donor Information
| Age | 82 |
|---|---|
| Age Category | Adult |
| Sex | Male |
Disease Information
| Disease | Mantle cell lymphoma |
|---|---|
| Lineage | Lymphoid |
| Subtype | Mantle Cell Lymphoma |
| OncoTree Code | MCL |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-002485_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Asp281Glu (c.843C>G) | Hemizygous | - | Unknown, PubMed=16434369 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Amelogenin
X,Y
CSF1PO
10,11
D13S317
8,13
D16S539
9,12
D18S51
16
D19S433
16
D21S11
29,33.2
D2S1338
17
D3S1358
17
D5S818
12
D7S820
8
D8S1179
11
FGA
19,21
Penta D
10,11
Penta E
5,12
TH01
8,9
TPOX
8,12
vWA
14,18
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines
Loading gene expression data...
Publications
Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.
Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.
Clin. Cancer Res. 24:3967-3980(2018).
Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma.
Touzeau C., Le Gouill S., Amiot M., Pellat-Deceunynck C.
Blood 128:2808-2818(2016).
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
OncoImmunology 3:e954893.1-e954893.12(2014).
A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines.
Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.
Cytometry A 87:285-288(2015).
Development and characterization of a Mantle Cell Lymphoma Cell Bank in the American Type Culture Collection.
O'Connor O.A.
Leuk. Lymphoma 56:2114-2122(2015).
Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma.
Lenz G., Stegmeier F.
Nat. Med. 20:87-92(2014).
Establishment of the MAVER-1 cell line, a model for leukemic and aggressive mantle cell lymphoma.
Lestani M., Menestrina F., Chilosi M.
Haematologica 91:40-47(2006).